ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159.6 USD | -2.04% |
|
-2.55% | +2.99% |
| 22/05 | Strides Pharma Arm Gets US FDA's Approval for Generic Stomach Ulcer Drug | MT |
| 17/05 | Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target | MT |
Presenter SpeechSteve Scala (Analysts)Well, good afternoon, and welcome to the AbbVie session ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
26/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
159.6
USD
Average target price
182.3
USD
Spread / Average Target
+14.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.99% | 28TCr | |
| +37.74% | 72TCr | |
| +32.22% | 59TCr | |
| -2.07% | 37TCr | |
| +20.25% | 33TCr | |
| +16.60% | 24TCr | |
| +9.77% | 21TCr | |
| -5.15% | 21TCr | |
| +7.43% | 17TCr | |
| +2.81% | 17TCr |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc. Presents at 42nd Annual Cowen Health Care Conference, Mar-08-2022 12
